Neulasta On-body Injector Makes Sure Drug Administered Following Chemo
Neulasta (pegfilgrastim) is administered to patients the day after chemotherapy to boost the production of white blood cells that help fight infection. Now a new product from Amgen, the manufacturer of Neulasta, will allow clinicians to stick a patch to a patient’s skin right after chemo that will deliver the full dose of the medication a day later.
This will guarantee that the patients receive the Neulasta while letting them rest comfortably at home after therapy. Additionally, one less visit per patient will free up a lot of valuable time at the clinic.
Some details from Amgen:
In addition to the On-body Injector, the Neulasta Delivery Kit includes a specifically designed Neulasta prefilled syringe along with HCP and Patient Instructions for Use and a Quick Reference Guide. On the same day as a chemotherapy session, the HCP initiates Neulasta administration by using the co-packaged syringe to fill the injector and activate it. The On-body Injector is then applied to the patient, to deliver Neulasta approximately 27 hours after the administration of cytotoxic chemotherapy. Activation of the injector leads to the subsequent insertion of the subcutaneous cannula while under HCP supervision. The HCP then reviews and provides the patient with the Patient Instructions for Use, which includes information about the On-body Injector for Neulasta and what the patient can expect while wearing it.